Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | PPARA | Q07869 | 1/20 | 0.47 |
| ▸ | APEX1 | P27695 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14775994 | 0.85 | NPC1 (0.50) | NPC1PKMRAB9APPARAAPEX1 | |
| SCHEMBL2684459 | 0.85 | NPC1 (0.52) | NPC1PKMRAB9APPARAAPEX1 | |
| SCHEMBL100763 | 0.81 | NPC1 (0.48) | NPC1PKMRAB9APPARAAPEX1 | |
| SCHEMBL2684347 | 0.78 | PPARA (0.56) | NPC1PKMRAB9APPARAAPEX1 | |
| SCHEMBL2684142 | 0.72 | NPC1 (0.55) | NPC1PKMRAB9AAPEX1SMN1; SMN2 | |
| SCHEMBL6946494 | 0.72 | NPC1 (0.49) | NPC1PKMRAB9ASMN1; SMN2LMNA | |
| SCHEMBL6946491 | 0.72 | NPC1 (0.49) | NPC1PKMRAB9ASMN1; SMN2LMNA | |
| SCHEMBL474201 | 0.70 | NPC1 (0.45) | NPC1PKMRAB9APPARAAPEX1 | |
| SCHEMBL10995472 | 0.70 | MAPT (0.58) | PPARASMN1; SMN2TSHRLMNAALDH1A1 | |
| SCHEMBL581421 | 0.69 | GAA (0.55) | PKMAPEX1SMN1; SMN2TSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8748441-B2 | Therapeutic uses of quinazolinedione derivatives | SANOFI (FR) | 2014-06-10 | — | — | US | disclosed |
| US-20120058987-A1 | THERAPEUTIC USES OF QUINAZOLINEDIONE DERIVATIVES | SANOFI (FR) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058987-A1 | THERAPEUTIC USES OF QUINAZOLINEDIONE DERIVATIVES | SLC5A2, SLC5A1, PPARD | NPC1 509/4885PKM 570/4885RAB9A 3883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.